Chronic Kidney Failure
Conditions
Keywords
Hyperphosphataemia, Phosphate binder
Brief summary
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to determine how well a range of different doses of fermagate are tolerated by the subjects in the trial.
Detailed description
High levels of phosphate in the blood are linked with serious effects, due to calcium imbalances (high levels of parathyroid hormone (PTH), bone disease, formation of calcium deposits in the body, and blood-vessel disease. Current guidelines indicate that blood phosphorus levels should be maintained between 1.13 to 1.78 mmol/L in patients who receive hemodialysis. The purpose of this study is to determine the range of dosages which are tolerated by patients with hyperphosphatemia, undergoing haemodialysis.
Interventions
DRUGFermagate
Film coated tablet 500mg
DRUGSevelamer HCl
tablet 800mg
Sponsors
Ineos Healthcare Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects on active haemodialysis, aged 18 years or over who are able to comply with study procedures * Written informed consent given * On a stable haemodialysis regimen (three times per week) for at least 3 months and be unlikely to change their dialysis prescription during the study period * On a stable dose of phosphate binder for at least 1 month prior to screening * Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium- or iron-containing products and preparations, other than the study medication * Willing to avoid any intentional changes in diet such as fasting, dieting or overeating * On a dialysate magnesium ion concentration of ≤1.0 mmol/L for at least 1 month prior to screening
Exclusion criteria
* Received a cardiac transplant * Heart failure according to New York Heart Association (NYHA) Functional IV Classification * Participation in any other clinical trial using an investigational product or device within the previous 4 weeks * A significant history of alcohol, drug or solvent abuse in the opinion of the investigator * Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn * Clinically significant laboratory findings (at screening for this subject population) in the opinion of the investigator * Any history of recent clinically significant malignancy * A significant illness (excluding renal disease) in the 4 weeks before screening * A history of poorly controlled epilepsy * Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device * Allergy to magnesium iron hydroxycarbonate or sevelamer or any component of the formulations * Any condition that affects the reliability of measuring QT interval, for example, an irregular heart rhythm such as atrial fibrillation or frequent ectopic activity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of intolerance | 10 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of QTc interval | 10 weeks |
| Change from baseline in serum electrolytes | 10 weeks |
| Change from baseline in parathyroid hormone (PTH) | 10 weeks |
| Reduction of serum magnesium removal during dialysis | 10 weeks |
Countries
United Kingdom
Outcome results
None listed